Accounting for Biotech Equity: No Longer Easy for Big Pharma
In the wake of several disastrous minority equity investments, drug companies are playing closer attention to where and how they account for minority equity when they put together partnerships. Accounting practices vary year-to-year and even case-by-case, but most drug companies are trying to neutralize expenses as soon as possible.
You may also be interested in...
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.
Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.